Development asset linked to BioNTech SE in public FDA and regional records. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
pharma · Non-small Cell Lung Cancer · Solid Tumors
BioNTech SE
BioNTech SE drug portfolio — 35 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
An der Goldgrube 12, Mainz, Rhineland-Palatinate 55131, DE HQ
2008 Founded
5,119 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- An der Goldgrube 12, Mainz, Rhineland-Palatinate 55131, DE
- Founded
- 2008
- Employees
- 5,119
- Programs
- 23
- Drugs
- 35
- Patents
- 25
BioNTech SE pipeline
Portfolio lens on 35 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
BioNTech SE drug portfolio — 35 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to BioNTech SE in public FDA and regional records.
-
Development asset linked to BioNTech SE in public FDA and regional records.
-
atezolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death 1 ligand 1.
- Target
- Programmed cell death 1 ligand 1
- Mechanism
- Programmed cell death 1 ligand 1 inhibitor
-
Development asset linked to BioNTech SE in public FDA and regional records.
-
Development asset linked to BioNTech SE in public FDA and regional records.
-
Development asset linked to BioNTech SE in public FDA and regional records.
-
US regulatory status: approved.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
cemiplimab
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in BioNTech SE's portfolio. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
Development asset linked to BioNTech SE in public FDA and regional records.
-
docetaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
Development asset linked to BioNTech SE in public FDA and regional records.
-
Development asset linked to BioNTech SE in public FDA and regional records.
-
enoxaparin sodium
Blood and blood forming organs (B01)US regulatory status: approved. Molecular target: Antithrombin-III.
- Target
- Antithrombin-III
- Mechanism
- Antithrombin-III activator
-
eribulin
Antineoplastic and immunomodulating agents (L01)Antineoplastic and immunomodulating agents (L01) compound in BioNTech SE's portfolio. Mechanism: Tubulin inhibitor.
- Mechanism
- Tubulin inhibitor
-
Development asset linked to BioNTech SE in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor alpha agonist
-
US regulatory status: approved. Molecular target: DNA topoisomerase II.
- Target
- DNA topoisomerase II
- Mechanism
- DNA topoisomerase II inhibitor
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- Thymidylate synthase inhibitor
-
US regulatory status: approved. Mechanism: DNA polymerase (alpha/delta/epsilon) inhibitor.
- Mechanism
- DNA polymerase (alpha/delta/epsilon) inhibitor
-
Development asset linked to BioNTech SE in public FDA and regional records.
-
Development asset linked to BioNTech SE in public FDA and regional records. Mechanism: DNA topoisomerase I inhibitor.
- Mechanism
- DNA topoisomerase I inhibitor
-
Development asset linked to BioNTech SE in public FDA and regional records.
-
Various (V04) compound in BioNTech SE's portfolio.
-
US regulatory status: approved. Molecular target: DNA.
- Target
- DNA
- Mechanism
- DNA inhibitor
-
paclitaxel
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Tubulin.
- Target
- Tubulin
- Mechanism
- Tubulin inhibitor
-
pembrolizumab
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Programmed cell death protein 1.
- Target
- Programmed cell death protein 1
- Mechanism
- Programmed cell death protein 1 inhibitor
-
US regulatory status: approved. Molecular target: Dihydrofolate reductase.
- Target
- Dihydrofolate reductase
- Mechanism
- Thymidylate synthase inhibitor
-
Development asset linked to BioNTech SE in public FDA and regional records.
-
Development asset linked to BioNTech SE in public FDA and regional records.
-
Development asset linked to BioNTech SE in public FDA and regional records.
-
Development asset linked to BioNTech SE in public FDA and regional records.
-
Development asset linked to BioNTech SE in public FDA and regional records.